This was a well-done research study. The research design was well-thought out and the researchers directly answer the questions they are asking. Their claims are backed up by their data. However, it is not relevant to all young breast cancer survivors, because this study only looked at ER+ breast cancer. Oncotype DX cannot be used for Triple Negative Breast Cancer because there are no hormone receptors. The study also did not consider whether BRCA mutation status would affect the results.